| 51 |
32981695 | Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. | 2020 Nov |
1 |
| 52 |
33006584 | PARP inhibition as frontline therapy in ovarian cancer. | 2020 Sep |
2 |
| 53 |
33068886 | Newly diagnosed ovarian cancer: Which first-line treatment? | 2020 Dec |
4 |
| 54 |
33112397 | Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. | 2020 Oct 1 |
2 |
| 55 |
33147530 | A functional polymorphism in the poly(ADP-ribose) polymerase-1 gene is associated with platinum-based chemotherapeutic response and prognosis in epithelial ovarian cancer patients. | 2020 Dec |
3 |
| 56 |
33692936 | Comparative Efficacy and Safety of PARP Inhibitors as Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis. | 2020 |
1 |
| 57 |
29961768 | Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. | 2019 Jan |
2 |
| 58 |
30540581 | Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. | 2019 Feb |
1 |
| 59 |
30672100 | PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms. | 2019 Apr |
1 |
| 60 |
30797591 | ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers. | 2019 May |
1 |
| 61 |
30895466 | PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review. | 2019 Jun |
3 |
| 62 |
30919167 | Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer. | 2019 Mar 27 |
1 |
| 63 |
31074636 | Veliparib: a new therapeutic option in ovarian cancer? | 2019 Jun |
1 |
| 64 |
31091037 | [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]. | 2019 May 15 |
1 |
| 65 |
31194214 | Immune Checkpoint and Poly(ADP-Ribose) Polymerase Inhibition for Recurrent Platinum-Resistant Ovarian and Metastatic Triple-Negative Breast Cancers. | 2019 Aug 1 |
1 |
| 66 |
31478762 | Olaparib in the treatment of ovarian cancer. | 2019 Oct |
1 |
| 67 |
31562799 | Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. | 2019 Dec 19 |
1 |
| 68 |
31629204 | Parp inhibitors as maintenance treatment in platinum sensitive recurrent ovarian cancer: An updated meta-analysis of randomized clinical trials according to BRCA mutational status. | 2019 Nov |
1 |
| 69 |
31685558 | Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. | 2019 Nov |
1 |
| 70 |
31738050 | Synthesis, Cytotoxicity, and Mechanistic Investigation of Platinum(IV) Anticancer Complexes Conjugated with Poly(ADP-ribose) Polymerase Inhibitors. | 2019 Dec 2 |
3 |
| 71 |
31907114 | Verapamil enhances the sensitivity of oxaliplatin to tumor cells by influencing the PARP pathway. | 2019 Dec 1 |
1 |
| 72 |
29396858 | Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models. | 2018 Jul 1 |
1 |
| 73 |
29397193 | The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. | 2018 Apr |
1 |
| 74 |
29750420 | Latest clinical evidence and further development of PARP inhibitors in ovarian cancer. | 2018 Jun 1 |
2 |
| 75 |
29871906 | PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey. | 2018 Sep 1 |
1 |
| 76 |
30067614 | Management of newly diagnosed or recurrent ovarian cancer. | 2018 Jun |
1 |
| 77 |
30080919 | Using PARP Inhibitors in Advanced Ovarian Cancer. | 2018 Jul 15 |
1 |
| 78 |
30082520 | Association of Base Excision Repair Gene Polymorphisms with the Response to Chemotherapy in Advanced Non-Small Cell Lung Cancer. | 2018 Aug 20 |
1 |
| 79 |
30228165 | Defective DNA repair in hereditary ovarian cancers: Implications for therapy. | 2018 Nov 1 |
1 |
| 80 |
30278221 | PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection. | 2018 Nov |
3 |
| 81 |
28471247 | The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer. | 2017 Jun |
1 |
| 82 |
28487881 | Whole-genome sequencing identifies homozygous BRCA2 deletion guiding treatment in dedifferentiated prostate cancer. | 2017 May |
2 |
| 83 |
29109859 | Candidate synthetic lethality partners to PARP inhibitors in the treatment of ovarian clear cell cancer. | 2017 Nov |
2 |
| 84 |
29232464 | Treatment of recurrent ovarian cancer. | 2017 Nov 1 |
1 |
| 85 |
26693899 | Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer. | 2016 Jan |
1 |
| 86 |
26984416 | What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? | 2016 May |
2 |
| 87 |
27127105 | PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. | 2016 May |
1 |
| 88 |
27155850 | Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry. | 2016 Sep |
2 |
| 89 |
27655641 | Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma. | 2016 Nov 8 |
1 |
| 90 |
27736844 | PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. | 2016 Nov 8 |
1 |
| 91 |
27756336 | Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study. | 2016 Oct 19 |
2 |
| 92 |
27821802 | Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review. | 2016 Dec 20 |
1 |
| 93 |
27884198 | Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. | 2016 Nov 24 |
1 |
| 94 |
25304989 | Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation. | 2015 Feb |
1 |
| 95 |
25779564 | Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. | 2015 Apr 20 |
2 |
| 96 |
25991068 | Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. | 2015 May 20 |
1 |
| 97 |
26206420 | An overview of early investigational therapies for chemoresistant ovarian cancer. | 2015 |
4 |
| 98 |
26269716 | Informative gene network for chemotherapy-induced peripheral neuropathy. | 2015 |
1 |
| 99 |
26374559 | Clinical Trials of Poly(ADP-Ribose) Polymerase Inhibitors for Cancer Therapy: A Review. | 2015 |
1 |
| 100 |
26646960 | [Individualized treatment for ovarian cancer may become possible]. | 2015 Dec 8 |
1 |